4//SEC Filing
Evoke Pharma Inc 4
Accession 0001209191-13-046790
$EVOKCIK 0001403708operating
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 5:48 PM ET
Size
26.4 KB
Accession
0001209191-13-046790
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
LVP GP III, LLC
10% Owner
Transactions
- Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners) - Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying) - Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying) - Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
LATTERELL PATRICK F
10% Owner
Transactions
- Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying) - Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
LVP LIFE SCIENCE VENTURES III L.P.
10% Owner
Transactions
- Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying) - Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying) - Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
LVP III Partners LP
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying) - Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying) - Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
LVPMC, LLC
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying) - Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
LVP III Associates, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2013-09-30+52,711→ 52,711 total(indirect: Directly owned by Associates) - Conversion
Series A Preferred Stock
2013-09-30−263,566→ 0 total(indirect: Directly owned by Associates)→ Common Stock (52,711 underlying) - Conversion
Series A Preferred Stock
2013-09-30−131,784→ 0 total(indirect: Directly owned by Partners)→ Common Stock (26,356 underlying) - Conversion
Common Stock
2013-09-30+1,054,262→ 1,054,262 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
2013-09-30+26,356→ 26,356 total(indirect: Directly owned by Partners) - Conversion
Series A Preferred Stock
2013-09-30−5,271,317→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (1,054,262 underlying)
Holdings
- 5,250(indirect: Directly owned by LVPMC)
Common Stock
Footnotes (5)
- [F1]The outstanding shares of Series A Preferred Stock automatically converted on a five-to-one basis into shares of Common Stock rounded down to the next whole number for no additional consideration immediately prior to the consummation of the Issuer's initial public offering.
- [F2]The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. (Continued on Footnote 3.)
- [F3]GP III may be deemed to have sole voting power and dispositive power over the shares held by LVP III, Associates and Partners. Each of GP III and Patrick Latterell, the managing member of GP III and the manager of LVPMC, may be deemed to share voting and dispositive power over the reported securities and disclaim beneficial ownership of the reported securities held by LVPMC, LVP III, Associates and Partners except to the extent of any pecuniary interest therein. Kenneth J. Widder, M.D., as a member of GP III, may be deemed to share voting and dispositive power over the reported securities held by LVP III, Associates and Partners, and disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
- [F4]The securities are immediately convertible.
- [F5]The securities have no expiration date.
Documents
Issuer
Evoke Pharma Inc
CIK 0001403708
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001403708
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 5:48 PM ET
- Size
- 26.4 KB